The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer

PURPOSE: Panitumumab is a human monoclonal antibody targeting the epidermal growth factor receptor for the treatment of wild-type RAS metastatic colorectal cancer (mCRC). Currently, no dedicated clinical studies have evaluated the effect of organ impairment on the pharmacokinetics of panitumumab. He...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Michael Z., Prenen, Hans, Dutta, Sandeep, Upreti, Vijay V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367910/
https://www.ncbi.nlm.nih.gov/pubmed/34213592
http://dx.doi.org/10.1007/s00280-021-04319-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367910/
https://www.ncbi.nlm.nih.gov/pubmed/34213592
http://dx.doi.org/10.1007/s00280-021-04319-w

Ejemplares similares